First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts
An investigational CAR T-cell therapy that hospital researchers in Spain believe they could produce at a third of the price of commercially available CART19 products has been accepted onto the European Medicines Agency's priority medicines scheme.
You may also be interested in...
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add one new product – Lumykras, Amgen’s treatment for advanced non-small cell lung cancer.